Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study

Abstract Objective We aimed to ascertain the efficacy and safety of transdermal rotigotine (2 and 3 mg/24 h) in Japanese patients with restless legs syndrome (RLS). Methods In our double-blind placebo-controlled study, 284 Japanese patients with idiopathic RLS were randomly assigned to receive rotig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sleep medicine 2013-11, Vol.14 (11), p.1085-1091
Hauptverfasser: Inoue, Yuichi, Shimizu, Tetsuo, Hirata, Koichi, Uchimura, Naohisa, Ishigooka, Jun, Oka, Yasunori, Ikeda, Junji, Tomida, Takayuki, Hattori, Nobutaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objective We aimed to ascertain the efficacy and safety of transdermal rotigotine (2 and 3 mg/24 h) in Japanese patients with restless legs syndrome (RLS). Methods In our double-blind placebo-controlled study, 284 Japanese patients with idiopathic RLS were randomly assigned to receive rotigotine 2 mg/24 h or 3 mg/24 h, or placebo, for 13 weeks. The primary endpoint was the change in International Restless Legs Syndrome Study Group rating scale (IRLS) total score. Results The placebo-subtracted decreases in IRLS total score for rotigotine 2 mg/24 h and 3 mg/24 h were −2.8 ± 1.3 and −3.1 ± 1.3, respectively, which were significant ( P < 0.05). The interaction between baseline Pittsburgh Sleep Quality Index (PSQI) and treatment group for the change in IRLS total score was significant, indicating greater improvements in IRLS total score in patients with severe insomnia. Overall, 80.0%, 86.2%, and 51.6% of patients in the rotigotine 2 mg/24 h, 3 mg/24 h, and placebo groups, respectively, experienced adverse events (AEs) including application site reactions in 42.1%, 50.0%, and 7.4% of patients, respectively. None of the AEs were severe. Conclusions Our results showed that rotigotine was effective without major safety concerns at doses of up to 3 mg/24 h in Japanese patients with RLS.
ISSN:1389-9457
1878-5506
DOI:10.1016/j.sleep.2013.07.007